TABLE 3.

Neurodevelopmental Outcome

Early Dexamethasone Group (n = 23)Control Group (n = 22)OR or Difference Between Means (95% CI)
Major cranial ultrasound abnormalities  at 12 mo of corrected age5 (21.7)6 (27.3)0.740 (0.189–2.900)
 Periventricular leukomalacia1 (4.3)1 (4.5)0.954 (0.055–16.28)
 Persistent ventricular dilatation4 (17.4)5 (22.7)0.715 (0.164–3.110)
 PHH2 (8.7)2 (9.1)0.952 (0.122–7.427)
Cerebral palsy2 (8.7)3 (13.6)0.603 (0.090–4.010)
 Spastic quadriplegia1 (4.3)2 (9.1)0.454 (0.038–5.408)
 Spastic hemiplegia1 (4.3)03.00 (0.115–77.71)
 Ataxia01 (4.5)0.305 (0.011–7.900)
Major neurosensory impairment3 (13)5 (22.7)0.510 (0.106–2.454)
 Blindness2 (8.7)1 (4.5)2.00 (0.168–23.79)
 Poor vision00
 Severe deafness02 (9.1)0.183 (0.008–4.033)
 Moderate hearing loss1 (4.3)2 (9.1)0.454 (0.038–5.408)
IQ score85.8 ± 13.9 (60–104)85.6 ± 16.3 (50–110)0.20 (−9.29–8.89)
 >9011 (47.8)11 (50)0.916 (0.284–2.953)
 70–909 (39.1)8 (36.4)1.125 (0.336–3.761)
 <703 (13)3 (13.6)0.950 (0.170–5.303)
Behavior abnormalities3 (13)5 (22.7)0.510 (0.106–2.454)
  • Data presented as mean ± SD (range) or number (%).